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We aimed to determine the effects of the oral direct renin inhibitor aliskiren on in vivo oxidative stress in
atrial ﬁbrillation (AF) patients. In this study, 150 mg oral direct renin inhibitor aliskiren was administered
once daily to 12 permanent AF patients. Aliskiren signiﬁcantly reduced urinary excretion of the oxidative
stress biomarker 8-iso-prostglandin F2α and serum levels of matrix metalloproteinase-2(MMP-2). We
concluded that aliskiren reduces in vivo oxidative stress and serum MMP-2 levels in patients with
permanent AF.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Activation of the renin–angiotensin–aldosterone system (RAAS) in
the atrial tissue is a point of concern in patients with atrial ﬁbrillation
(AF), since increased generation of angiotensin II activates NADPH
oxidase and enhances oxidative stress in vivo in these individuals
[1,2]. Enhanced oxidative stress in turn activates matrix metallopro-
teinases (MMPs) [3], which are key enzymes in atrial remodeling
[4,5]. The serum MMP-2 content was reported to be an independent
predictor of post-ablation AF recurrence [6]. The oral direct renin
inhibitor aliskiren is expected to block the RAAS completely when
supplemented in treatment with conventional RAAS inhibitors, since
addition of aliskiren was found to reduce in vivo oxidative stress and
albuminuria in hypertensive diabetic patients with chronic kidney
disease [7]. The aim of this study was to determine the effects of
aliskiren on in vivo oxidative stress in AF patients.
2. Materials and methods
2.1. Patients and study protocol
Informed consent was obtained from each patient for partici-
pation in this study, which was approved by the Institutional
Ethics Committee of Higashi-osaka City General Hospital on
January 26, 2012. Enrolled were 12 patients (8 men and 4 women;
mean age, 72.8 years) with permanent AF and hypertension who
visited our outpatient clinic from October 2010 to June 2012.
Inclusion criteria were (1) plasma levels of brain-type natriuretic
peptide (BNP) 4100 pg/mL on at least two occasions prior to
enrollment; (2) no episodes of admission because of chronic heart
failure (CHF) worsening; and (3) non-smoking status. CHF was
treated using conventional medicines, including angiotensin-
converting enzyme inhibitor, β-blockers, angiotensin II receptor
blockers, diuretics, and mineral corticoid receptor antagonists. An
optimal dose of warfarin was also prescribed. Excluded criteria
were as described elsewhere [8]. Lastly, 150 mg aliskiren once
daily was administered for at least 3 months. The conventional
medicines were not changed during the protocol. Immediately
before and 3 months after aliskiren administration, blood and
urine were sampled for biochemical measurements.
To assess the normal range of urinary excretion of 8-iso-
prostaglandin F2α (8-iso-PG-F2α), a reliable biomarker of in vivo
oxidative stress, 23 subjects who visited our Health Screening
Department were selected. None of these subjects had AF, hyper-
tension, diabetes mellitus, dyslipidemia, or history of heart failure
and none were current smokers (14 men and 9 women; mean age,
53714 years).
2.2. Biochemical measurements
Immunoreactive 8-iso-PGF2α was measured in urine by using
an enzyme immunoassay kit, as described previously (Cayman
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Chemical, Ann Arbor, MI, USA) [8]. Commercially available kits
were used to measure plasma BNP, serum MMP-2, plasma renin
activity, and serum aldosterone [8].
2.3. Statistical analyses
Data were expressed as mean7standard deviation. The differ-
ences between pre- and post-aliskiren administration were ana-
lyzed using Student's t-test. Differences between the AF patients
and the normal control group were analyzed using the unpaired
Student's t-test. Po0.05 was considered signiﬁcant.
3. Results
Aliskiren reduced urinary 8-iso-PG-F2α excretion (3407137 to
285797 g/mg creatinine, P¼0.02). Urinary 8-iso-PGF2α excretion
after aliskiren administration in the AF group was similar to that in
the normal control group (229776 pg/mg creatinine; n¼23;
Table 1). Aliskiren reduced serum MMP-2 levels (13057421 vs.
11587323 ng/mL, P¼0.04) but not plasma BNP (2437137 vs.
2307161 pg/mL) or aldosterone levels (8.273.6 vs. 8.873.1
ng/dL) (Table 1). Echocardiographic parameters, including the
dimensions of the left atrium and ventricle, remained unaltered
during the study protocol (data not shown).
4. Discussion
Aliskiren reduced in vivo oxidative stress and serum MMP-2
levels in patients with permanent AF, although it did not alter the
symptoms of CHF or plasma BNP levels. Further, these biochemical
markers seemed to have no association with echocardiographic
parameters. One of the reasons for this lack of an association might
be the irreversible atrial remodeling occurring in permanent AF.
This study had some limitations. First, we did not measure
myocardial MMP-2 activity but serum MMP-2 levels. MMP-2
activity in tissue might better reﬂect atrial remodeling. Second,
we did not measure the biomarkers in a placebo-controlled group.
To determine whether aliskiren affects atrial remodeling, further
investigation is necessary with a larger population of not only
permanent but also paroxysmal AF patients and a longer observa-
tion period.
5. Conclusions
Aliskiren reduced in vivo oxidative stress and serum MMP-2
levels in patients with permanent AF.
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Table 1
Biochemical parameters.
Aliskiren P value
Pre Post
Urinary 8-iso-PG-F2α (pg/mg creatinine) 3407137 285797 0.02
Serum MMP-2 (ng/mL) 13057421 11587323 0.04
Plasma BNP (pg/mL) 2437137 2307161 n.s.
Systolic BP (mmHg) 138.8721.6 128.3719.2 0.07
Serum creatinine (mg/dL) 0.8870.20 0.9570.27 n.s.
Serum K (meq/L) 4.1370.39 4.0570.32 n.s.
Plasma renin activity (ng mL1 h1) 1.8572.40 1.6272.18 0.07
Plasma aldosterone content (ng/dL) 8.273.6 8.873.1 n.s.
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